ReviewMethodist DeBakey cardiovascular journal2026
Relapsing Pericarditis: Prediction of Relapses, Risk Scores, and Role of Exercise Restriction.
Review in Methodist DeBakey cardiovascular journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsing pericarditis (RP) is a chronic inflammatory disorder characterized by two or more episodes of acute pericarditis flares after a minimum of a 4-week symptom-free period. Recurrent pericarditis develops in approximately 15% to 30% of patients following an initial episode of acute pericarditis, and nearly half of these individuals experience subsequent recurrences. Although the course is heterogeneous, RP has substantial morbidity and impaired quality of life implications and is associated with pericardial complications, including cardiac tamponade and constrictive pericarditis. This review summarizes current knowledge about clinical perspectives, predictors, and risk stratification tools for relapses in RP and critically appraises the evolving role of exercise restriction as part of RP management. Many adverse prognosticators for RP in clinical, laboratory, multimodality cardiac imaging, and treatment factors have been identified from clinical trials, observational studies, and experiences of managing RP patients. Several risk scores have been recently developed to assist in risk stratification and treatment guidance for RP patients, such as the Athens, Torino, INFLA, and Klein scores. There is also growing evidence for exercise restriction strategies with a focus on practical individualized strategies in the multimodal treatment of RP that have been included in recent pericarditis guidance documents. Multicenter external validation and randomized trials remain necessary to assess the roles and performance of risk scores and exercise restriction in treating RP to improve their clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.